Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 12/20 | 0.37 |
| ▸ | GLP1R | P43220 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
| ▸ | GIPR | P48546 | 1/20 | 0.36 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.34 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716574 | 0.92 | IDH1 (0.34) | GCGRCE1SLC6A9SLC6A5NAMPT | |
| SCHEMBL720865 | 0.89 | GCG (0.32) | GCGGLP1RGCGRGIPR | |
| SCHEMBL721158 | 0.88 | GCG (0.39) | GCGRCE1 | |
| SCHEMBL718868 | 0.88 | GCGR (0.49) | GCGGLP1RGCGRGIPR | |
| SCHEMBL3399863 | 0.87 | KMT2A (0.38) | GCGGCGRRCE1SLC6A9 | |
| SCHEMBL719341 | 0.87 | SLC6A9 (0.41) | GCGGLP1RGCGRGIPRSLC6A9 | |
| SCHEMBL717738 | 0.87 | GCGR (0.49) | GCGGLP1RGCGRGIPR | |
| SCHEMBL27834377 | 0.84 | GCG (0.40) | GCGRCE1SLC6A9 | |
| SCHEMBL721090 | 0.83 | ABL1 (0.40) | GCGGLP1RGCGRGIPRRCE1 | |
| SCHEMBL718930 | 0.83 | GCG (0.39) | GCGGLP1RGCGRGIPRRCE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102015641-B | Heterocyclic compound | TAKEDA PHARMACEUTICAL | 2014-01-01 | — | — | CN | disclosed |
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | GCG 35/4885GLP1R 5/4885GCGR 90/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | GCG 35/4885GLP1R 5/4885GCGR 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.